Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Employees - 53,
CEO - Mr. David J. Lennon Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 122.08M
Altman ZScore(max is 10): -3.41, Piotroski Score(max is 10): 3, Working Capital: $61502000, Total Assets: $85698000, Retained Earnings: $-314381000, EBIT: -62427000, Total Liabilities: $16830000, Revenue: $25070000
- Current Price $3.39 - Analyst Target Price $3.00| Ticker | AADI |
| Index | - |
| Curent Price | 3.39 |
| Change | 46.12% |
| Market Cap | 122.08M |
| Average Volume | 270.02K |
| Income | -61.69M |
| Sales | 25.07M |
| Book Value/Share | 2.80 |
| Cash/Share | 1.74 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 89 |
| Moving Avg 20days | 40.11% |
| Moving Avg 50days | 52.67% |
| Moving Avg 200days | 78.73% |
| Shares Outstanding | 24.61M |
| Earnings Date | Nov 06 BMO |
| Inst. Ownership | 48.67% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 4.87 |
| Price/Book | 1.21 |
| Price/Cash | 1.95 |
| Price/FCF | - |
| Quick Ratio | 4.54 |
| Current Ratio | 4.89 |
| Debt/Equity | 0.01 |
| Return on Assets | -54.75% |
| Return on Equity | -65.95% |
| Return on Investment | -88.77% |
| Gross Margin | 87.39% |
| Ops Margin | -253.63% |
| Profit Margin | -246.06% |
| RSI | 83.00 |
| BETA(β) | 0.64 |
| From 52week Low | 180.17% |
| From 52week High | 29.08% |
| EPS | -2.29 |
| EPS next Year | -1.01 |
| EPS next Qtr | -0.47 |
| EPS this Year | 9.02% |
| EPS next 5 Year | - |
| EPS past 5 Year | 11.87% |
| Sales past 5 Year | 225.26% |
| EPS Y/Y | 3.12% |
| Sales Y/Y | 7.80% |
| EPS Q/Q | 23.31% |
| Sales Q/Q | 21.03% |
| Sales Surprise | 9.36% |
| EPS Surprise | -0.55% |
| ATR(14) | 0.21 |
| Perf Week | 40.66% |
| Perf Month | 52.70% |
| Perf Quarter | 77.49% |
| Perf Year | 64.56% |
| Perf YTD | 67.82% |
| Target Price | 3.00 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer